Clinico-pathological research for predictive factors of the treatment effects in radiation therapy combined with or without chemotherapy for lung cancer

点击翻译按钮获取中文摘要

In the patients with peripheral stage I non-small cell lung cancer treated with stereotactic body radiotherapy, the 5-year overall survival rate, cause-specific survival rate and local progression-free rate were 63%, 74% and 72%, respectively. But the patients with squamous cell carcinoma of the lung had a worse prognosis. The immunohistochemical study for EGFR mutation showed that the heterogeneity of gene mutation commonly developed in the various types of lung cancer. The 6B6 antibody staining was specific for EGFR mutation and considered to be useful for screening patients effective to EGFR TKI.